Eli Lilly | LLY - Le Bénéfice D'Exploitation

Prix De L'Action
954.52
Variation Quotidienne
34.75 3.78%
Mensuellement
-6.23%
Annuel
16.66%
Q2 Prévisions
851.89




Le Bénéfice D'Exploitation Changement Date
AbbVie USD 5.81B 1.23B 2025-12
Abbott USD 2.25B 73M 2025-12
ALKERMES USD -10.95M 100.03M 2025-12
Amgen USD 3.96B 464M 2025-12
AstraZeneca USD 2.97B 4.48B 2025-12
Baxter International USD -214.2M 415.4M 2025-12
Biogen USD 659.6M 192.2M 2025-09
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Coherus Biosciences USD -39.08M 3.65M 2025-12
Drreddys Laboratories INR 14.33B 2.51B 2025-12
Eli Lilly USD 8.99B 599.9M 2025-12
Gilead Sciences USD 2.96B 551M 2025-12
GlaxoSmithKline GBP 1.44B 1.35B 2025-12
Glaxosmithkline GBP 2.3B 1.46B 2025-12
J&J USD 5.59B 1.81B 2025-12
Medtronic USD 1.74B 40M 2025-12
Merck USD 6.24B 318M 2025-12
Neurocrine Biosciences USD 227.9M 11.4M 2025-12
Novartis USD 4.06B 437M 2025-12
Novartis USD 4.06B 521M 2025-12
Novo Nordisk DKK 32.38B 1.7B 2025-12
Perrigo USD 84.4M 9M 2025-12
Pfizer USD 4.65B 3.99B 2025-12
Phibro Animal Health USD 54.99M 2.36M 2025-12
Prestige Brands USD 82.49M 2.82M 2025-12
Regeneron Pharmaceuticals USD 898.6M 211.3M 2025-12
Roche Holding CHF 9.56B 3.8B 2025-12
Sanofi EUR 1.7B 2.17B 2025-12
Sanofi EUR 1.5B 2.29B 2025-12
United Therapeutics USD -14.6M 403.9M 2025-12
Zoetis USD 835M 101M 2025-12